Patients with severe forms of MS had encouraging results with a autologous hematopoietic stem cell transplantation in a large-scale real-world cohort.
The MS-STAT2 trial of a high-dose simvastatin has failed to slow progression of disability in patients with secondary ...
Secondary imaging endpoints generally were in the same direction as the primary endpoint. Plasma levels of NfL ... in people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback